Pneumococcal vaccination for RA patients in TNF-α antagonists [2]

Rheumatology

Volumn 43, Issue 4, 2004, Pages 523-

  Wright, Stephen ^a   Taggart, A J ^a  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL MENINGITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LETTER; LOBAR PNEUMONIA; NECROTIZING FASCIITIS; NONHUMAN; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; OPPORTUNISTIC INFECTIONS; PNEUMOCOCCAL VACCINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1842844289     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh167     Document Type: Letter

References (10)

1. Moots R, Taggart AJ, Walker D. Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology 2003;42:614-6.
2. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF alpha therapy. Rheumatology 2003;42:617-21.
3. Butler J, Breiman R, Campbell J. Pneumococcal polysaccharide vaccine efficacy. JAMA 1993;270:1826-31.
4. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years experience in Northern Ireland. Ulster Med J 2002;71:101-5.
5. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
6. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
7. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumour necrosis factor alpha in the pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997;65:257-60.
8. Watkins J. Pneumococcal vaccine use by UK doctors. In: First International Symposium on Pneumococcus and Pneumococcal Disease, Helsinki, 1998; Suppl. 1: 102-3.
9. Elkayam O, Caspi D, Paran D, Reitblat T, Litinsksy I, Yaron M. Effect of anti-tumour necrosis factor alpha therapies, on the immunogenicity of pneumococcal vaccination in patients with rheumatic diseases. Arthritis Rheum 2002;46:(Suppl. 9): 5340.
10. Cairns AP, Taggart AJ. Tumour necrosis factor inhibitors: maximising patients' safety. Rheumatology 2003;42:188-9.